Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study.
Psoriasis is a common skin disease affecting 1%-3% of the world's population with significant impacts on quality of life. There is a great need for therapies that are efficacious and safe, not only for the short-term, but also for long-term management. Dovobet/ Daivobet/ Taclonex is a product combining two molecules, calcipotriol and betamethasone dipropionate, that may offer psoriatic patients with an option for maintenance therapy. The efficacy and safety of this combined formulation when used over a 4-week period is well documented. A recent publication in the British Journal of Dermatology discusses the safety of this product when used for 52 weeks.